Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching

CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026. The system is designed to provide high‑resolution HLA genotyping in under three hours while supporting rapid assay turnaround and enhanced resolution. It expands the company’s pre‑transplant laboratory portfolio alongside AlloSeq Tx and QTYPE to address a range of throughput requirements and use cases.

AlloSeq Nano employs a streamlined long‑read library preparation coupled with a single‑step amplification and preparation workflow. In early access testing, hands‑on time was approximately 45 minutes to assay eleven HLA loci plus ABO in a single test. The assay incorporates probe redundancy to help minimize allele dropout, and its long‑read sequencing approach reduces phasing ambiguities, supporting robust performance and accuracy across loci.

To introduce AlloSeq Nano, CareDx will host a satellite symposium at EFI 2026 on Thursday, April 23. The session will include scientific and educational discussions focused on AlloSeq Nano and CareDx’s transplant diagnostics portfolio.

CareDx will also present several abstracts at EFI 2026, highlighting its work across laboratory, clinical, and technical aspects of transplant diagnostics. Presentations will feature AlloSeq cfDNA in kidney and lung transplant settings, along with QTYPE®, which enables rapid ABO genotyping alongside HLA typing.

Related Links
CareDx